Exploratory study on classification of chronic obstructive pulmonary disease combining multi-stage feature fusion and machine learning

Junfeng Peng1*, Mi Zhou2, Kaiqiang Zou1, Xiongyong Zhu1, Jun Xu1, Yi Teng1, Feifei Zhang1 and Guoming Chen1

Abstract

Background: Due to the complexity and high heterogeneity of the acute exacerbation of chronic obstructive pulmonary disease (AECOPD), the guidelines (global initiative for chronic obstructive, GOLD) is unable to fully guide the treatment of AECOPD.

Objectives: To provide a rapid treatment in line with the development of the AECOPD after admission. In this paper, we propose a multi-stage feature fusion (MSFF) framework combining machine learning to track the diseases deterioration risk of the AECOPD.

Methods: First, we identify 408 AECOPD patients as the study population. Then, feature segment and fusion methods are applied to generate the phased data set. Finally, human studies are designed to evaluate the performance of the MSFF framework.

Results: The experimental results show that the proposed framework is potential to obtain the full-process tracking of deterioration risk for the AECOPD patients. The proposed MSFF framework achieves a higher overall accuracy average and F1 scores than the four physician groups i.e., IM, Surgery, Emergency, and ICU.

Conclusions: The proposed MSFF model may serve as a useful disease tracking tool to estimate the deterioration risk at each stage, and finally achieve the disease monitoring and management for AECOPD patients.

Keywords: Machine learning, Medical decision support system, Real-world data, Chronic obstructive pulmonary disease

Background

Chronic obstructive pulmonary disease (COPD), as a common disease characterized by an irreversible persistent airflow limitation, causes the decline in the quality of life of patients [1, 2]. COPD as a major cause of chronic morbidity and mortality is a global health threat, and will become the third leading cause of death in the world by 2030 [3]. The Acute Exacerbation of COPD (AECPOD) is a key event in the disease course, which causes a sharp decline of lung function and a significant increase in mortality [4, 5]. The increasing frequency of exacerbations and hospitalizations is the daily manifestation of the deterioration of AECOPD [6]. In addition, the prevalence proportion of depressive symptoms is found to be significantly higher among individuals with AECOPD as compared to control [7]. However, timely and reliable risk identification of AECOPD has important clinical significance for prevention and early interventional therapy [8]. In order to identify the deteriorate risk for
any given AECOPD patient, physicians often use hypothetical reasoning. From this initial feature set of patients (basic information, past history, current medical history), a physician forms a basic diagnostic set, and then updates the basic diagnostic set based on further clinical data (complications, tests, and examinations) [9]. Thus, the physician who acts like a classifier of sorts reaches final diagnostic set through the cycle of the above process. However, due to the complexity of AECOPD and the lack of consensus, it is a tricky task for clinicians to identify the start of deterioration for AECOPD [10–12]. In addition, the limitations of the human brain and lack of benign statistical and analytical techniques make the identification of acute deterioration events a huge challenge for physicians.

In recent years, Artificial Intelligence (AI) techniques have become potentially powerful tools for the diagnosis and management of diseases, mimicking and even aiding clinical decision-making of human physicians [13–15]. For AI-enabled medical applications, the number of cancer-related publications was the highest, followed by heart diseases and stroke, vision impairment, alzheimers disease, and depression [16]. The intelligent diagnosis of AECOPD requires further research.

To improve the therapeutic effect of the AECOPD, many scholars study the disease based on artificial intelligence. Swaminatha et al. proposed a supervised Gradient Enhanced Random Forest (GERF) model after the collection of the clinical data from AECOPD patients. The prediction accuracy of GERF reaches 88% of that of clinicians [17]. Wang et al. developed a transfer learning algorithm based on balanced probability distribution to predict the risk of exacerbation in patients with AECOPD and the model achieved a good prediction result on the small data sets [18]. Altan et al. used the deep learning method to extract the features of lung sound of AECOPD patients, then the extracted features were utilized to build the model to predict AECOPD. The method achieved 93.67% prediction accuracy [19]. Wang et al. employed a variety of machine learning methods to predict the risk of exacerbation in patients with AECOPD, and the experimental results showed that support vector machine (SVM) performed better than the other models [20]. Ganguly et al. took advantage of the forward feature selection method to select features, and then employed the logistic regression model to achieve the identification of AECOPD. The area under curve (AUC) of the developed model was 0.710 [21]. We can find that the common methods based on artificial intelligence tend to ignore the timeliness of clinical data.

However, the timeliness of clinical data is the key to the real world research (RWD) [22]. The neglect of timeliness of clinical data brings the intelligent diagnosis of AECOPD three challenges at least [23]. First, AECOPD is a highly heterogeneous and complex disease required to be monitored in time. Second, a large amount of treatment data is produced over time. As the treatments progress, a lot of important clinical data sets are gradually produced by time. The mining of the generation time in these clinical data is supportive of clinical decision-making. Third, clinical data is strictly time-sensitive which means that the diagnosis significance of expired data is little. Thus, a model considering the timeliness of clinical data has practical clinical significance to track the diseases deterioration risk. Thus, we propose a multi-stage feature fusion (MSFF) framework to achieve this goal (Fig. 1).

The experimental results show that the proposed framework is potential to obtain the full-process tracking of deterioration risk for the AECOPD patients. The framework can also be extended to the deterioration risk monitoring for the other chronic diseases. The main contributions of this paper are summarized as follows: (1) A method based on machine learning is proposed to track the disease deterioration risk of the AECOPD with the generation time of clinical data. (2) We evaluate the proposed method by real data set from the Third Affiliated Hospital, Sun Yat-sen University.

The remainder of this paper is organized as follows. Section 2 designs the multi-stage feature fusion for deterioration risk trace. In Sect. 3, the evaluation of the proposed framework is carried out. Discussion are provided to the proposed MSFF framework in Sect. 4. We conclude our work in Sect. 5.

**Methods**

**Study participants**

We conduct the research under the guidance of the Third Affiliated Hospital, Sun Yat-sen University (TAHSYU) Institutional Review Board (IRB), protocol [2019]-02-334-01. 408 AECOPD patients are identified retrospectively by the International Classification of Diseases, Tenth Revision, Clinical Modification (J44.100, J44.101) from the respiratory unit database of TAHSYU, a major Chinese large-scale Medical Center. Data masking techniques are applied to the AECOPD patients before analysis.

The distribution of AECOPD patients is shown in Table 1. The AECOPD inpatients those need the intensive care unit are marked as serious group, while those don't need as mild group. We can find that the proportion of AECOPD patients with serious group is 46.1%, while the proportion of mild group is 53.9%.

**Feature fusion**

We define the data set of AECOPD patients as \( P \). A patient in the collection can be defined as \( P_i \). We assume that \( P_i \) contains \( n \) clinical features, then \( P_i \) can be express as:
where \( p_i \in P, \ n \in N \). Meanwhile, we assume \( p^n_i \) as the clinical feature generated through \( k \) periods (phases or stages), so that the clinical features of \( p_i \) can be divided into \( k \) parts by periods, and then the clinical data of \( p_i \) with multiple time periods can be denoted as:

\[
p_i = (p^1_i, p^2_i, ..., p^n_i),
\]

(1) where \( p^n_{i,k} \) represents the clinical data of the patient \( i \) produced at period phase \( k \). We use \( y_{i,k} \) to indicate the severity level of the AECOPD patient \( p_i \). Then, we can define the phased deterioration risk as:

\[
p_i = (p^1_{i,1}, p^2_{i,1}, ..., p^m_{i,1}, p^1_{i,2}, ..., p^m_{i,2}, ..., p^1_{i,k}, ..., p^m_{i,k}, y_{i,n}),
\]

(2) Let \( y_{i,1} = y_{i,2} = ... = y_{i,n} \), so that we can predict the final deterioration risk based on the phased clinical data. We define \( \text{seg}_{i,k}^w \) as (5) to represent all the clinical features \( (w) \) generated at phase \( k \) of the patient.

\[
\text{seg}_{i,k}^w = (p^1_{i,k}, p^2_{i,k}, ..., p^w_{i,k}),
\]

(4) where the number of the collected clinical features at phase \( k \) can be represented as \( w = c(k) \). Thus, we can define the single patient time-based phased accumulating clinical data in the previous \( k \) stages as \( \text{acci}_{i,k} \) shown by Eq. (6).

\[
\text{acci}_{i,k} = (\text{seg}_{i,1}^{c(1)}, \text{seg}_{i,2}^{c(2)}, ..., \text{seg}_{i,k}^{c(k)}).
\]

(5) While all the patients’ time-based phased accumulating clinical data can be expressed by:

\[
D_k = (\text{seg}_{1,1}, \text{seg}_{2,1}, ..., \text{seg}_{k,1}),
\]

(6) where \( D_k \) and \( y_i \) are the \( k \)-th input and output of the model, respectively.

While all the patients’ time-based phased accumulating clinical data can be expressed by:

\[
D_k = (D_{k-1}, \text{seg}_{k}),
\]

(7) where \( D_{k-1} \) indicates the input of stage \( k - 1 \), \( \text{seg}_k \) denotes the \( k \)-th input of stage \( k \), respectively.

Modeling
Data modeling begins after the feature fusion. Assuming that there is a hypothesis \( f \) on the AECOPD patient data set \( D \) through machine learning method. Then, the prediction of the staged deterioration risk for the AECOPD patient \( p_i \) is calculated by:
where $\hat{Y}_k$ denotes the deterioration risk of prediction for the AECOPD patient data set. $f$ denotes the machine learning model to be solved. $D_k$ represents the AECOPD patient data of stage $k$. $Y_k$ depicts the true deterioration risk of the AECOPD patient data set. The difference $\epsilon$ between $\hat{Y}_k$ and $Y_k$ can be expressed by:

$$\epsilon = |\hat{Y}_k - Y_k|,$$

(9)

$f$ can be simple or complex model. The smaller the difference $\epsilon$ is, the better the model performs. To search the best model $f$ from the data set $D_k$, the difference $\epsilon$ should be minimized. In real-world study, considering the complexity of clinical data, it may be more appropriate to build simple models and complex ones together.

Framework of multi-stage feature fusion

We define the multi-stage feature fusion framework below. In this section, we propose the novel framework by combining the machine learning model and phased accumulating clinical data (Fig. 1). The proposed MSFF framework is presented and discussed in framework 1. The input of the MSFF framework is the phased accumulating clinical data sets shown by Eq. (6). The output is the queue of the phased deterioration risk of the patients. The goal of MSFF framework (Fig. 1) is to obtain the classification results on the phased data set defined by Eq. (6). The framework is as follows. Step 1: set the prediction results empty. Step 2 to step 4: sort the input $D$, segment the input $D$ into $K$ pieces, and define the cumulative data successively. Step 5 to step 11: for each phased data, construct the machine learning model successively and calculate the prediction results. Step 12: return the phased prediction results.

Algorithm 1 MSFF

Input:
The phased data set $D$ and the $K$ periods;

Output:
The queue of the phased deterioration risk $res$;

1: initialize the queue of the phased deterioration risk results $res \leftarrow (0, 0, \ldots, 0)$ ;
2: $SD \leftarrow SortByTime(D)$.
3: $SDK \leftarrow Segment(SD, K)$.
4: $SDKA \leftarrow ACC(SDK) = D_1, D_2, \ldots, D_K$
5: for each $D_i$ in $SDKA$ do do
6: $D_{i\_train} \leftarrow CreateDataPartition(D_i, p)$.
7: $D_{i\_test} \leftarrow CreateDataPartition(D_i, 1 - p)$.
8: $M_i \leftarrow Model(D_{i\_train})$
9: $res_i \leftarrow predict(M_i, D_{i\_test})$.
10: $res \leftarrow res_i$.
11: end for
12: return $res$

Human studies

We carry out a study to compare the performance of MSFF framework with that of human physicians on the validation set of data set of $D_4$. We select 16 junior physicians from the department of Internal Medicine (IM), Surgery, Intensive Care Unit (ICU), and Emergency. Each group consists of 4 clinicians (four at the intermediate level and four at the primary level). Each physician in each group reads a random subset of 326 AECOPD patients’ clinical records from the independent training data set and assign a severity rating (serious or mild) to the 82 random validation data set. Then, we evaluate the diagnostic classification performance of each physician group using an $F_1$ score and overall accuracy.
Results
Framework initialization
In the real world medical scene, the clinical phase $k$ becomes bigger with the development of the treatment. For the convenience of experimental demonstration, we identify 4 segmentations and 40 features as the input of the MSFF framework (shown in Table 2). Then, considering the high accuracy, robustness and fastness of the ensemble of decision trees, random forest model is employed as the model $f$ to predict the disease deterioration risk for AECDOP [24, 25]. Finally, we compare our MSFF framework with the clinicians on the phased data set $D = (\text{Seg}_1, \text{Seg}_2, \text{Seg}_3, \text{Seg}_4)$. We implemented the MSFF framework using the development platform of R3.5.1. 90% of the whole dataset is randomly separated into the training data set, while the rest of (10%) of the whole dataset is set as independent test dataset. In order to verify the generalization of the model, 10-fold CV is employed. We apply the cross-validated gridsearch approach to optimize the machine learning models and tune the hyperparameters.

Table 1: Basic information of study participants (values are expressed as mean ± standard deviation)

|                    | Mild group | Serious group |
|--------------------|------------|--------------|
| Number of cases    | 220 (53.9%)| 188 (46.1%)  |
| Smoking            | 173 (78.6%)| 132 (70.2%)  |
| Age                | 78.8 ± 9.1 | 81.5 ± 9.2   |
| Sex (male)         | 188 (85.5%)| 157 (83.5%)  |
| Sex (female)       | 32 (14.5%) | 31 (16.5%)   |
| Number of hospitalization | 3.6 ± 2.6  | 6.5 ± 7.3   |
| Temperature        | 36.8 ± 0.5 | 36.7 ± 0.6  |
| Respiratory rate   | 21.7 ± 3.2 | 24.7 ± 6.4  |
| Systolic pressure  | 133.1 ± 19.1| 131.6 ± 24.7|
| Diastolic pressure | 75.8 ± 12.3 | 74.4 ± 13.4 |
| Cor pulmonary      | 43 (19.5%)  | 64 (34.0%)   |
| Bronchiectasis     | 13 (5.91%)  | 8 (4.26%)    |
| Hypertension       | 96 (43.64%) | 73 (38.83%) |
| Diabetes           | 21 (9.55%)  | 34 (18.09%) |
| Coronary disease   | 24 (10.91%) | 29 (15.43%) |
| Chronic kidney diseases | 6 (2.73%)   | 4 (2.13%)   |
| Malignant tumour   | 18 (8.18%)  | 16 (8.51%)   |
| Cerebrovascular disease | 9 (4.09%)   | 8 (4.26%)   |
| Viral hepatitis    | 3 (1.36%)   | 2 (1.06%)    |
| Liver cirrhosis    | 1 (0.45%)   | 1 (0.53%)    |

Table 2: Feature selected in the phased data sets of AECOPD patients

| Phase | Data snippet | Description | Feature sets |
|-------|--------------|-------------|--------------|
| $k = 1$ | Seg_1 | Basics | Gender, age, et al. |
| $k = 2$ | Seg_2 | Comorbidities | Pulmonary heart disease, et al. |
| $k = 3$ | Seg_3 | Inflammations | C-reactive protein, et al. |
| $k = 4$ | Seg_4 | Metabolism | Oxygen saturation, et al. |

Table 3: Performance evaluation of the MSFF on the stage data D1–D4 generated by cross-validation method

| Phased data set | Model | acc | sn | sp | mcc | Curve |
|-----------------|-------|-----|----|----|-----|-------|
| D1              | RF    | 0.750 | 0.773 | 0.722 | 0.495 | 0.748 |
|                 | SVM   | 0.725 | 0.864 | 0.556 | 0.445 | 0.710 |
|                 | KNN   | 0.675 | 1.000 | 0.278 | 0.418 | 0.639 |
|                 | PLS   | 0.775 | 0.773 | 0.778 | 0.548 | 0.775 |
| D2              | RF    | 0.750 | 0.773 | 0.722 | 0.495 | 0.748 |
|                 | SVM   | 0.700 | 0.864 | 0.500 | 0.395 | 0.682 |
|                 | KNN   | 0.600 | 0.773 | 0.389 | 0.175 | 0.581 |
|                 | PLS   | 0.750 | 0.818 | 0.667 | 0.492 | 0.742 |
| D3              | RF    | 0.800 | 0.909 | 0.667 | 0.601 | 0.788 |
|                 | SVM   | 0.775 | 0.818 | 0.722 | 0.544 | 0.770 |
|                 | KNN   | 0.625 | 0.773 | 0.444 | 0.231 | 0.609 |
|                 | PLS   | 0.725 | 0.818 | 0.611 | 0.441 | 0.715 |
| D4              | RF    | 0.825 | 0.864 | 0.778 | 0.646 | 0.821 |
|                 | SVM   | 0.800 | 0.864 | 0.722 | 0.595 | 0.793 |
|                 | KNN   | 0.700 | 0.909 | 0.444 | 0.406 | 0.677 |
|                 | PLS   | 0.850 | 0.864 | 0.833 | 0.697 | 0.849 |

D1, D2, D3 and D4 represent the AECOPD patient data of stage 1 to 4. At each stage, there are 408 samples.
accuracy and F1-score are used. The F1-measure and the overall accuracy (acc), Sensitive (sn), Specificity (sp), Matthews correlation coefficient (MCC) are the metrics with True Positives (TP), True Negative (TN), False Negatives (FN) and False Positives (FP). The receiver operating characteristic curve (ROC) are also employed to test the MSFF framework. Metrics are defined as follows:

\[
sp = \frac{TN}{TN + FP}, \quad (10)
\]

\[
sn = \frac{TP}{TP + FN}, \quad (11)
\]

### Table 4

Performance evaluation of the MSFF on the stage data D1–D4 generated by independent test (non-cross-validation method)

| Phased data set | Model | acc   | sn   | sp   | mcc   | Curve  |
|----------------|-------|-------|------|------|-------|--------|
| D1             | RF    | 0.750 | 0.773| 0.722| 0.495 | 0.748  |
|                | SVM   | 0.775 | 0.955| 0.556| 0.568 | 0.755  |
|                | KNN   | 0.575 | 0.773| 0.333| 0.118 | 0.553  |
|                | PLS   | 0.775 | 0.864| 0.667| 0.545 | 0.765  |
| D2             | RF    | 0.750 | 0.773| 0.722| 0.495 | 0.748  |
|                | SVM   | 0.675 | 0.818| 0.500| 0.338 | 0.659  |
|                | KNN   | 0.600 | 0.818| 0.333| 0.174 | 0.576  |
|                | PLS   | 0.775 | 0.864| 0.667| 0.545 | 0.765  |
| D3             | RF    | 0.700 | 0.727| 0.667| 0.394 | 0.697  |
|                | SVM   | 0.800 | 0.864| 0.722| 0.595 | 0.793  |
|                | KNN   | 0.600 | 0.818| 0.333| 0.174 | 0.576  |
|                | PLS   | 0.775 | 0.864| 0.667| 0.545 | 0.765  |
| D4             | RF    | 0.775 | 0.818| 0.722| 0.544 | 0.770  |
|                | SVM   | 0.800 | 0.955| 0.611| 0.614 | 0.783  |
|                | KNN   | 0.600 | 0.818| 0.333| 0.174 | 0.576  |
|                | PLS   | 0.775 | 0.864| 0.667| 0.545 | 0.765  |

D1, D2, D3 and D4 represent the AECOPD patient data of stage 1 to 4. At each stage, there are 408 samples.
The feature of the new data is equivalent to the D4.

The shortcoming of this paper includes lack of tracking data (anxiety and depression) of AECOPD patients after discharge from hospital because of the poor follow-up compliance of the study subjects. Medical imaging was not used during data acquisition as we used the lung function to determine the severity level. In the future, we will establish multicenter contracts to obtain more AECOPD patient data. We hope that the model's...
predictive power will be improved by more abundant and reliable real-world training data.

**Conclusions**

To achieve the real-time monitoring of acute exacerbation disease such as AECOPD, we dig deep into the generation time of the clinical features, dynamically divides the clinical data into multiple stages, and utilizes the machine learning methods to perform the deterioration risk warning in stages, eventually achieves the real-time monitoring for the acute exacerbation diseases. The proposed MSFF framework is able to track the phased deterioration risk of AECOPD patients with real world data. Our model achieves a higher classification performance than the four junior physician groups. The data segmentation proposed in this paper conforms to the process of clinical diagnostic reasoning. With the increase of clinical information, the predictive performance of the proposed MSFF framework may be gradually improved. Further work will investigate the natural language processing technology to dig out potentially valuable information from the electronic medical records, such as the patient's past history, present medical history, course of illness, discharge summary and other text records [26].

**Abbreviations**

RWS: Real world search; COPD: Chronic obstructive pulmonary disease; AECOPD: Acute exacerbation of chronic obstructive pulmonary disease; GOLD: Global initiative for chronic obstructive; MSFF: Multi-stage feature fusion; RF: Random forest; SVM: Support vector machine; PLS: Partial least-squares; KNN: K-nearest neighbor.

**Acknowledgements**

Not applicable.

**Authors’ contributions**

JFP designed and implemented the MSFF framework, and was a major contributor in writing the manuscript. MZ were responsible for preprocessing the data and checking the results. KFZ and GMLT gave constructive suggestions for the manuscript. All authors read and approved the final manuscript.

**Funding**

The funders provided financial support. This work has been supported by Science and Technology Planning Project of Guangzhou(No.201804010280), Natural Science Foundation of Guangdong Province (No.2018A0303130169). Scientific research platforms and projects of colleges and universities in Guangdong Province (No.2021ZDZX3016). Scientific research platforms and projects of colleges and universities in Guangdong Province (No.20212DZX3016). Young innovative talents project of colleges and universities in Guangdong Province (No.2021KQNCX061).

**Availability of data and materials**

The data that support the findings of this study are available from the third affiliated hospital, sun yat-sen university but restrictions apply to the availability of these data, which were used under license for the current study, and so are not publicly available. Data are however available from the authors upon reasonable request and with permission of the third affiliated hospital, sun yat-sen university.

**Declarations**

**Ethics approval and consent to participate**

The study was approved by Ethics Committee of Third Affiliated Hospital, Sun yat-sen University (TAHYU) Institutional Review Board (IRB), protocol [2019]-02-334-01. All methods were carried out in accordance with relevant guidelines and regulations.

**Consent for publication**

Not applicable.

**Competing interests**

The authors declare that they have no competing interests.

**Author details**

1 School of Computer Science, Guangdong University of Education, Guangzhou 510066, China. 2 The Third Affiliated Hospital, Sun Yat-sen University, Guangzhou 510640, China.

**Received: 6 April 2021 Accepted: 1 December 2021**

**Published online:** 14 December 2021

**References**

1. Seemungal TA, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ, Wedzicha JA. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998;157:1418–22.

2. Ra SW, Kwon YS, Yoon SH. Sputum bacteriology and clinical response to antibiotics in moderate exacerbation of chronic obstructive pulmonary disease. Clin Respir J. 2018;12:1424–32.

3. Burden of COPD [in:] Chronic respiratory diseases. World Health Organization. 2015. http://www.who.int/respiratory/copd/burden/en, 12 h 22 min a.m.

4. Donaldson GC, Seemungal TA, Bhowmik A, Wedzicha JA. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax. 2002;57:847–52.

5. Kanner RE, Anthonsen NR, Connett JE. Lower respiratory illnesses promote FEV1 decline in current smokers but not ex-smokers with mild chronic obstructive pulmonary disease: results from the lung health study. Am J Respir Crit Care Med. 2001;164:358–64.

6. Ngo CQ, Phan DM, Vu G. Inhaler technique and adherence to inhaled medications among patients with acute exacerbation of chronic obstructive pulmonary disease in Vietnam. Int J Environ Res Public Health. 2019;16:185.

7. Zhang MW, Ho RC, Cheung MWL, Maik A. Prevalence of depressive symptoms in patients with chronic obstructive pulmonary disease: a systematic review, meta-analysis and meta-regression. Gen Hosp Psychiatry. 2011;33:217–23.

8. Singh D, Agusti A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease: the GOLD science committee report 2019. Eur Respir J. 2019;53:5.

9. Wilkinson TM, Donaldson GC, John RH. Early therapy improves outcomes of exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2004;169:1298–303.

10. Chandra D, Tsai CL, Carmargo CA. Acute exacerbations of COPD: delay in presentation and the risk of hospitalization. COPD. 2009;6:95–103.

11. Seemungal TA, Wedzicha JA. Acute exacerbations of COPD: the challenge is early treatment. COPD. 2009;6:79–81.

12. Weng SF, Reps J, Kai J, Ganibaldi JM, Qureshi N. Can machine-learning improve cardiovascular risk prediction using routine clinical data. PLoS ONE. 2017;12.e0174944.

13. Wang Q, Wang H, Wang L, Yu F. Diagnosis of chronic obstructive pulmonary disease based on transfer learning. IEEE Access. 2020:47370–83.

14. Altan G, Kutlu Y, Allahverdi N. Deep learning on computerized analysis of chronic obstructive pulmonary disease. IEEE J Biomed Health Inform. 2020;24:1344–50.

15. Tran BX, Vu GT. Global evolution of research in artificial intelligence in health and medicine: a bibliometric study. J Clin Med. 2019;8:360.
16. Liang H, Tsui BY. Evaluation and accurate diagnoses of pediatric diseases using artificial intelligence. Nat Med. 2019;25:433–8.
17. Swaminatha S, Qirko K, Smith T, et al. A machine learning approach to triaging patients with chronic obstructive pulmonary disease. PLoS One. 2017;12(11):e0188532.
18. Wang Q, Wang H, Wang L, et al. Diagnosis of chronic obstructive pulmonary disease based on transfer learning. IEEE Access. 2019;8:47370–83.
19. Altan G, Kutlu Y, Allahverdi N. Deep learning on computerized analysis of chronic obstructive pulmonary disease. IEEE J Biomed Health Inform. 2020;24(5):1344–50.
20. Wang C, Chen X, Du L, Zhan Q, et al. Comparison of machine learning algorithms for the identification of acute exacerbations in chronic obstructive pulmonary disease. Comput Methods Programs Biomed. 2020;188:105267.
21. Ganguly K, Carlander U, Garessus E, et al. Computational modeling of lung deposition of inhaled particles in chronic obstructive pulmonary disease (COPD) patients: identification of gaps in knowledge and data. Crit Rev Toxicol. 2017;49(2):160–73.
22. Bonamici SHR.34-114th Congress (2015–2016): 21st Century Cures Act[EB/OL]. https://www.congress.gov/bill/114th?congress=house?bill=34,2017.
23. Food US, and Drug Administration. Prescription Drug User Fee Act (PDUFA)-PDUFA?: Fiscal Years 2018?2022[EB/OL]. https://www.fda.gov/forindustry/userfees/prescriptiondruguserfee/ucm446608.htm, 2017.
24. Quinlan JR. C4.5: programs for machine learning. New York: Morgan Kaufman, 1993.
25. Breiman L, Raymond A. Random forests machine learning. J Clin Microbiol. 2001;25:199–228.
26. Chen L, Song L, Shao Y. Using natural language processing to extract clinically useful information from Chinese electronic medical records. Int J Med Inform. 2019;124:6–12.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.